To the Editor We commend the authors1 for addressing the understudied topic of direct immunofluorescence (DIF) test utility with a robust 8-year single-center review. In this series, all autoimmune blistering dermatosis (AIBD) cases would have been detected with immunoglobulin (Ig) G, IgA, and C3, and all vasculitis cases with IgA, C3, and fibrinogen. The authors concluded that the DIF panel should be customized based on indication. Because of the observed lack of utility of DIF for certain indications, including suspected porphyria, lichen planus (LP), or lupus erythematosus, the authors recommend against DIF in these settings. We challenge these conclusions for several reasons.